First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Journal of Thoracic Oncology Année : 2021

First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA

Domaines

Cancer

Dates et versions

inserm-03540850 , version 1 (24-01-2022)

Identifiants

Citer

D. Carbone, T. Ciuleanu, M. Cobo, M. Schenker, B. Zurawski, et al.. First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA. Journal of Thoracic Oncology, 2021, 16 (10), pp.S862. ⟨10.1016/j.jtho.2021.08.061⟩. ⟨inserm-03540850⟩
24 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More